• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Virol. Nucleozin Targets Cytoplasmic Trafficking of Viral Ribonucleoprotein-Rab11 Complexes in Influenza A Virus Infection

Giuseppe

Emeritus
[Source: Journal of Virology, full text: (LINK). Abstract, edited.]

Nucleozin Targets Cytoplasmic Trafficking of Viral Ribonucleoprotein-Rab11 Complexes in Influenza A Virus Infection


Maria Joao Amorim<SUP>a</SUP>,<SUP>b</SUP>, Richard Y. Kao<SUP>c</SUP> and Paul Digard<SUP>a</SUP>,<SUP>d</SUP>
<SUP></SUP>
Author Affiliations: <SUP>a</SUP>Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom <SUP>b</SUP>Cell Biology of Viral Infection, Instituto Gulbenkian de Ci?ncia, Oeiras, Portugal <SUP>c</SUP>Department of Microbiology and Research Center of Infection and Immunology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong <SUP>d</SUP>The Roslin Institute, University of Edinburgh, Easter Bush, Midlothian, United Kingdom


ABSTRACT

Novel antivirals are needed to supplement existing control strategies for influenza A virus (IAV). A promising new class of drug, exemplified by the compound nucleozin, has recently been identified that targets the viral nucleoprotein (NP). These inhibitors are thought to act as ?molecular staples? that stabilize interactions between NP monomers, promoting the formation of nonfunctional aggregates. Here we detail the inhibitory mechanism of nucleozin, finding that the drug has both early- and late-acting effects on the IAV life cycle. When present at the start of infection, it inhibited viral RNA and protein synthesis. However, when added at later time points, it still potently blocked the production of infectious progeny but without affecting viral macromolecular synthesis. Instead, nucleozin blocked the cytoplasmic trafficking of ribonucleoproteins (RNPs) that had undergone nuclear export, promoting the formation of large perinuclear aggregates of RNPs along with cellular Rab11. This effect led to the production of much reduced amounts of often markedly smaller virus particles. We conclude that the primary target of nucleozin is the viral RNP, not NP, and this work also provides proof of the principle that IAV replication can be effectively inhibited by blocking cytoplasmic trafficking of the viral genome.


FOOTNOTES

Received 21 November 2012. Accepted 5 February 2013.

Address correspondence to Maria Joao Amorim, mjamorim@igc.gulbenkian.pt.

Published ahead of print 13 February 2013

Supplemental material for this article may be found at http://dx.doi.org/10.1128/JVI.03123-12.

Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
-------
 
Back
Top Bottom